Metotrexate Ebewe

Methotrexate, the active ingredient in Metotrexate Ebewe, is an antimetabolite (folate antagonist) presented as a sterile injectable solution for intramuscular, intravenous, subcutaneous use. It treats rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma and breast cancer in appropriate patients.

GNH USA supplies Metotrexate Ebewe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is employed in autoimmune and oncologic conditions where folate metabolism is a therapeutic target.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin cell proliferation and improves lesions. - Acute lymphoblastic leukemia: induces remission by inhibiting malignant cell proliferation. - Non‑Hodgkin lymphoma: contributes to tumor control as part of chemotherapy regimens. - Breast cancer: used in high‑dose protocols to enhance cytotoxic effect.

Methotrexate may cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects: - Nausea and vomiting. - Fatigue or malaise. - Mucositis or oral ulceration. - Alopecia (hair loss). - Elevated liver enzymes.

Serious or Rare Side Effects: - Bone marrow suppression leading to pancytopenia. - Severe infection due to immunosuppression. - Pulmonary toxicity, including interstitial pneumonitis. - Hepatotoxicity with fibrosis or cirrhosis. - Renal failure from precipitation of drug crystals. - Severe cutaneous reactions such as Stevens‑Johnson syndrome.

Use of Metotrexate Ebewe requires careful monitoring and specific safety measures.

- Pregnancy: contraindicated (Category X); avoid in women of childbearing potential. - Liver function: monitor hepatic enzymes regularly. - Renal function: assess creatinine clearance before initiation and during therapy. - Hematology: perform routine complete blood counts to detect marrow suppression. - Active infection: defer treatment until infection is resolved. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medicines that can increase toxicity or reduce efficacy.

Major Interactions (Avoid): - NSAIDs: may increase methotrexate serum levels and toxicity. - Penicillins: can enhance myelosuppression. - Live vaccines: risk of severe infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect renal clearance of methotrexate. - Azathioprine: additive immunosuppressive effect requiring close blood count monitoring.